Bright Minds Biosciences Inc.

NASDAQ:DRUG

Biotechnology

Healthcare
$20.76 +1.04%

+$0.62 today

Market cap
$204.78M
Beta
-0.11
P/E (TTM)
-29.8
EPS (TTM)
-$2.87
52W Low $23.18High $123.75

Volume 0.14M

Average 0.27M

DRUG Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Bright Minds Biosciences Inc.NASDAQ: DRUG

Selling, General & Admin · Q2 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of CA$2.23M rose 229.7% year over year, ahead of the +147.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 104.7% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.

Context

  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate of CA$0 (-100.0%) for the fiscal year ending Sep 2026, a slowdown from the +77.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$2.23M+104.7% QoQ
Last fiscal yearSep 2025
CA$2.57M+77.5% YoY
LTMMar 2026
CA$4.67M+147.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+229.7%-100.0%-329.7 pp
1 year+77.5%-100.0%-177.5 pp
3-year CAGR+0.2%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

CAD · from the income statement

Latest · FY2025
2.57M CAD
Year-over-year change
+77.5%
4-year CAGR
+2.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How DRUG compares with its peers on the latest reported figures

No competitor Selling, General & Admin figures are available to compare.

Income Statement

CAD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.31M12.18M5M1.18M11.08M
Selling, General & Admin2.31M2.55M2.2M1.45M2.57M
Operating Expenses8.62M14.98M7.39M2.82M13.94M
Depreciation & Amortization8.62M6.04K72.45K73.36K76.87K
EBITDA(27.64K)(14.96M)(7.3M)(2.73M)(12.15M)
EBITDA Margin—————
Operating Income(8.62M)(14.98M)(7.39M)(2.82M)(13.94M)
Operating Margin—————
Interest Income00030.13K1.52M
Interest Expense00000
Other Income / Expenses(27.64K)10.15K14.19K20.82K1.71M
Income Before Tax(8.65M)(14.96M)(7.37M)(2.8M)(12.23M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(8.65M)(14.96M)(7.37M)(2.8M)(12.23M)
Net Margin—————
EPS (Basic)(4.74)(6.15)(1.98)(0.65)(1.78)
EPS (Diluted)(4.74)(6.15)(1.98)(0.65)(1.78)
Weighted Avg Shares1.79M2.47M3.72M4.31M6.88M
Weighted Avg Shares (Diluted)1.79M2.47M3.72M4.31M6.88M

Bright Minds Biosciences Inc.

NASDAQ:DRUG

Intrinsic Alpha fair value

Locked

Current Price

$20.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.